Aggarwal et al. found that metastatic NSCLC patients with baseline bTMB ≥ 16 mutations/Mb and an absence of negative predictor mutations (STK11/KEAP1/PTEN and HER2 exon 20) were associated with improved PFS and durable clinical benefit in response to first line pembrolizumab treatment [101]. This evidence concerns the gene STK11 and non-small cell lung carcinoma.